PE20120015A1 - Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico - Google Patents

Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico

Info

Publication number
PE20120015A1
PE20120015A1 PE2011000159A PE2011000159A PE20120015A1 PE 20120015 A1 PE20120015 A1 PE 20120015A1 PE 2011000159 A PE2011000159 A PE 2011000159A PE 2011000159 A PE2011000159 A PE 2011000159A PE 20120015 A1 PE20120015 A1 PE 20120015A1
Authority
PE
Peru
Prior art keywords
perbb3
therapeutic agent
predicting
response
systems
Prior art date
Application number
PE2011000159A
Other languages
English (en)
Inventor
Birgit Schoeberl
Brian Harms
Francis David Gibbons
Jonathan Basil Fitzgerald
Matthew David Onsum
Ulrik Nielsen
William Kubasek
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of PE20120015A1 publication Critical patent/PE20120015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

REFERIDA A UN METODO PARA TRATAR A UN PACIENTE QUE TIENE UN TUMOR NEOPLASICO QUE COMPRENDE: A) OBTENER UNA MUESTRA DEL TUMOR; B) DETERMINAR EL NIVEL DE pErbB3 EN LA MUESTRA Y DEPENDIENDO DE LA CANTIDAD DE pErbB3 EN PORCENTAJE DE UN CULTIVO DE CELULAS ACHN SEGUIDO POR EL CULTIVO DE 20-24 HORAS EN MEDIO LIBRE DE SUERO; C) ADMINISTRAR AL MENOS UN AGENTE TERAPEUTICO ANTINEOPLASICO AL PACIENTE TAL COMO ANTICUERPO ANTI-ErbB3 SI EL NIVEL DE pErbB3 NO ES MENOR QUE 50% O UN ANTICUERPO DIFERENTE CUANDO EL NIVEL DE pErbB3 ES MENOR A 50%. DICHO METODO ES UTIL EN EL TRATAMIENTO DE TUMOR DE COLON, PULMON, RECTO, CEREBRO, MAMAS, RINON, ESTOMAGO, ENTRE OTROS
PE2011000159A 2008-08-15 2009-08-17 Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico PE20120015A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18905308P 2008-08-15 2008-08-15
US19470208P 2008-09-30 2008-09-30
US20820609P 2009-02-20 2009-02-20
US17036709P 2009-04-17 2009-04-17

Publications (1)

Publication Number Publication Date
PE20120015A1 true PE20120015A1 (es) 2012-01-26

Family

ID=41228727

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000159A PE20120015A1 (es) 2008-08-15 2009-08-17 Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico

Country Status (24)

Country Link
US (4) US8623592B2 (es)
EP (1) EP2318548B1 (es)
JP (1) JP2012500008A (es)
KR (1) KR20110044905A (es)
CN (1) CN102224255A (es)
AU (1) AU2009281721A1 (es)
BR (1) BRPI0917871A2 (es)
CA (1) CA2732658A1 (es)
CO (1) CO6341654A2 (es)
CR (1) CR20110128A (es)
DO (1) DOP2011000054A (es)
EA (1) EA022884B1 (es)
EC (1) ECSP11010872A (es)
ES (1) ES2433424T3 (es)
HK (1) HK1155782A1 (es)
IL (1) IL210865A (es)
MA (1) MA32630B1 (es)
MX (1) MX2011001764A (es)
NZ (1) NZ591137A (es)
PE (1) PE20120015A1 (es)
SV (1) SV2011003840A (es)
UA (1) UA104868C2 (es)
WO (1) WO2010019952A2 (es)
ZA (1) ZA201100921B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8927694B2 (en) * 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag Anti-HER3 antibodies and their applications
PL2544680T3 (pl) * 2010-03-11 2015-08-31 Merrimack Pharmaceuticals Inc Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
SG185366A1 (en) 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011159904A1 (en) * 2010-06-17 2011-12-22 The Trustees Of The University Of Pennsylvania Methods for predicting cellular signaling responses to combinatorial stimuli
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
SG193006A1 (en) 2011-03-02 2013-10-30 Berg Llc Interrogatory cell-based assays and uses thereof
EA201300996A1 (ru) 2011-03-11 2014-01-30 Мерримак Фармасьютикалс, Инк. Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2530462A1 (en) * 2011-06-03 2012-12-05 Merrimack Pharmaceuticals, Inc. Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (es) * 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
CN103959065B (zh) * 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
CN104160400A (zh) * 2011-12-16 2014-11-19 克里帝奥成果技术公司 用于确定癌症治疗的可编程细胞模型
CN108048521B (zh) * 2012-04-02 2022-05-27 博格有限责任公司 基于细胞的探询式分析及其应用
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
CA2876636C (en) * 2012-06-13 2022-09-13 Medimmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
KR101430309B1 (ko) * 2012-11-14 2014-08-13 이선우 바이오 3d 모델링 장치
ES2971536T3 (es) * 2012-11-21 2024-06-05 Janssen Biotech Inc Anticuerpos biespecíficos egfr/c-met
US10489717B2 (en) 2013-01-03 2019-11-26 Aetna, Inc. System and method for pharmacovigilance
US11424040B2 (en) * 2013-01-03 2022-08-23 Aetna Inc. System and method for pharmacovigilance
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
KR20140093347A (ko) * 2013-01-15 2014-07-28 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 처리에 의해 부작용을 유발하는 유전자 및 이를 이용한 약물 스크리닝 방법
JP2016535079A (ja) * 2013-09-30 2016-11-10 第一三共株式会社 核酸生体マーカー及びその使用
WO2015048804A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Protein biomarker and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US20150285817A1 (en) * 2014-04-08 2015-10-08 Biodesix, Inc. Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
US10482385B2 (en) 2014-09-11 2019-11-19 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN107750165A (zh) * 2015-04-17 2018-03-02 梅里麦克制药股份有限公司 借助塞里班土单抗的组合治疗
GB201508841D0 (en) * 2015-05-22 2015-07-01 Isis Innovation Treatment
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6382459B1 (ja) * 2015-06-15 2018-08-29 ナントミクス，エルエルシー 細胞系ゲノミクスからの薬物応答の患者特異的予測のためのシステムおよび方法
JP6836586B2 (ja) * 2015-09-29 2021-03-03 エイチティージー モレキュラー ダイアグノスティクス， インコーポレイテッド びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）を亜型決定するための方法
EP3429623A1 (en) 2016-03-15 2019-01-23 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3542290B1 (en) * 2016-11-17 2024-01-03 NantBio, Inc. Validation of inferred anticancer pathways
JP7404648B2 (ja) 2019-04-25 2023-12-26 富士通株式会社 治療薬提示方法、治療薬提示装置、及び治療薬提示プログラム
US20230088271A1 (en) * 2020-02-28 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Determining Spatial Accumulation of Signaling Molecules Within Tissue Samples
WO2021240263A1 (en) 2020-05-26 2021-12-02 Insilico Medicine Ip Limited Biological data signatures of aging and methods of determining a biological aging clock
WO2022058980A1 (en) 2020-09-21 2022-03-24 Insilico Medicine Ip Limited Methylation data signatures of aging and methods of determining a methylation aging clock
CN113049249A (zh) * 2020-12-31 2021-06-29 山东科技大学 一种电机轴承故障诊断方法及系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5344760A (en) * 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US6983227B1 (en) * 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DK0896586T4 (en) * 1996-03-27 2015-08-24 Genentech Inc ErbB3 antibodies.
CN1202247C (zh) * 1996-07-12 2005-05-18 基因技术股份有限公司 嵌合异源多亚基粘附素
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL202369B1 (pl) * 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE60139768D1 (de) * 2000-05-19 2009-10-15 Genentech Inc Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine k
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
WO2003011897A1 (en) * 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1421113A4 (en) * 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US7415359B2 (en) * 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
EP1495123B1 (en) * 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Erbb3 based methods and compositions for treating neoplasms
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
BRPI0408928A (pt) * 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
CA2534898A1 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20070059785A1 (en) * 2003-08-15 2007-03-15 Smithkline Beecham Corporation Biomarkers in cancer
CN100559203C (zh) * 2003-09-19 2009-11-11 Nxp股份有限公司 包括秘密的子模块的电子电路
US8554486B2 (en) * 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
BRPI0508286B8 (pt) * 2004-03-31 2021-05-25 Dana Farber Cancer Inst Inc método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores
EP1778270A4 (en) * 2004-05-05 2009-09-02 Merrimack Pharmaceuticals Inc BIS-SPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
ES2553264T3 (es) * 2004-05-27 2015-12-07 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
WO2005121380A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham Corporation Predictive biomarkers in cancer therapy
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
RU2410438C2 (ru) * 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
AU2005272848A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20060136139A1 (en) * 2004-10-12 2006-06-22 Elcock Adrian H Rapid computational identification of targets
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
EP1913160A2 (en) * 2005-07-29 2008-04-23 Bayer Healthcare LLC Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
CA2624613A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
JP2009532393A (ja) 2006-04-07 2009-09-10 コペンハーゲン ユニバーシティ ＥｒｂＢ受容体由来ペプチド断片
DK2032982T3 (da) 2006-05-05 2012-11-05 Univ Yale Anvendelse af subcellulær lokaliseringsprofiler som prognostiske eller prædiktive indikatorer
EP2047262A4 (en) * 2006-07-13 2011-03-16 Univ Yale PROGNOSTIC METHODS OF CANCER FROM THE SUBCELLULAR LOCATION OF BIOMARKERS
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
SI2129396T1 (sl) * 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
CL2008000614A1 (es) 2007-03-02 2008-09-05 Genentech Inc F Hoffmann La Ro Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
DK2076289T3 (da) * 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent

Also Published As

Publication number Publication date
US20170307631A1 (en) 2017-10-26
DOP2011000054A (es) 2011-04-30
WO2010019952A2 (en) 2010-02-18
KR20110044905A (ko) 2011-05-02
HK1155782A1 (en) 2012-05-25
IL210865A0 (en) 2011-04-28
US8623592B2 (en) 2014-01-07
CR20110128A (es) 2011-09-27
CA2732658A1 (en) 2010-02-18
ZA201100921B (en) 2014-06-25
ES2433424T3 (es) 2013-12-11
MA32630B1 (fr) 2011-09-01
EP2318548A2 (en) 2011-05-11
AU2009281721A1 (en) 2010-02-18
US20140127238A1 (en) 2014-05-08
NZ591137A (en) 2012-10-26
EP2318548B1 (en) 2013-10-16
CN102224255A (zh) 2011-10-19
IL210865A (en) 2014-04-30
SV2011003840A (es) 2011-07-06
BRPI0917871A2 (pt) 2017-06-20
CO6341654A2 (es) 2011-11-21
EA201100373A1 (ru) 2011-08-30
US20110159513A1 (en) 2011-06-30
JP2012500008A (ja) 2012-01-05
US20110027291A1 (en) 2011-02-03
WO2010019952A3 (en) 2010-06-24
EA022884B1 (ru) 2016-03-31
MX2011001764A (es) 2011-05-19
ECSP11010872A (es) 2011-09-30
UA104868C2 (uk) 2014-03-25

Similar Documents

Publication Publication Date Title
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
SG10201901076WA (en) Methods of treating alzheimer's disease
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
ATE461294T1 (de) Brustkrebsdiagnoseverfahren
EA201500156A3 (ru) Доставка антител посредством модульного домена распознавания
MY163057A (en) Means and methods for trating dlblcl
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
AR081209A1 (es) Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
EP2957642A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий

Legal Events

Date Code Title Description
FX Voluntary withdrawal